



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900

IN THE APPLICATION OF: Ko et al. : CASE NO.: PH-7054-A
SERIAL NO.: 09/981,833 : ART UNIT: 1624
FILED: October 18, 2001: EXAMINER: Unknown

FOR: Heterocyclic Piperidines as Modulators of Chemokine Receptor Activity

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- (X) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is set forth below.
- () The fee of **\$240.00** as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of **\$130.00** as set forth in §1.17(i)(1)

Please charge any deficiency or credit any overpayment to Deposit Account No. 193880. There are no listed references which are not in the English language.

RELATED CASE STATEMENT

<u>Attorney Docket #</u>	<u>App./Patent Number</u>	<u>Filing/Grant Date</u>	<u>Status</u>
PH-7050	09/465,286	12/17/1999	Pending
PH-7058	09/465,301	12/17/1999	Pending
PH-7150	09/465,948	12/17/1999	Pending
PH-7151	09/465,287	12/17/1999	Pending
PH-7152	09/466,442	12/17/1999	Pending
PH-7153	6,331,541	12/18/2001	Granted

Respectfully submitted,

Mary VanAtten

Mary K. VanAtten
Attorney for Applicants
Registration No. 39,408
Telephone: 302-467-5268

DATE: 7/16/02
Bristol-Myers Squibb Company
P. O. Box 4000
Princeton, NJ 08543-4000

RECEIVED

JUL 23 2002

RECH CENTER 1600/2900





Certificate of Mailing under 37 CFR 1.8

In the Application of: **Ko et al**

CASE NO.: **PH-7054-A**

APPLICATION NO.: **09/981,833**

GROUP ART UNIT: **1624**

FILED: **OCTOBER 18, 2001**

EXAMINER: **UNKNOWN**

FOR: **HETEROCYCLIC PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR
ACTIVITY**

I hereby certify that this correspondence, a Information Disclosure Statement (with 1449 form and references) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231

on July 17, 2002
Date

Denise Bierlein

Signature

Denise Bierlein

Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

RECEIVED

JUL 23 2002

TECH CENTER 1600/2900